Associations Between Nutritional Deficits and Physical Performance in Community-Dwelling Older Adults

Wan-Hsuan Lu, Kelly Virecoulon Giudici, Yves Rolland, Sophie Guyonnet, Jean-François Mangin, Bruno Vellas, and Philipe de Souto Barreto

Background: Whether multiple nutritional deficiencies have a synergic effect on mobility loss remains unknown. This study aims to evaluate associations between multi-nutritional deficits and physical performance evolution among community-dwelling older adults.

Methods: We included 386 participants from the Multidomain Alzheimer Preventive Trial (MAPT) (75.6 ± 4.5 years) not receiving omega-3 polyunsaturated fatty acid (PUFA) supplementation and who had available data on nutritional deficits. Baseline nutritional deficits were defined as plasma 25-hydroxyvitamin D < 20 ng/ml, plasma homocysteine > 14 µmol/L, or erythrocyte omega-3 PUFA index ≤ 4.87% (lower quartile). The Short Physical Performance Battery (SPPB), gait speed, and chair rise time were used to assess physical performance at baseline and after 6, 12, 24, 36, 48, and 60 months. We explored if nutrition-physical performance associations varied according to the presence of low-grade inflammation (LGI) and brain imaging indicators.

Results: Within-group comparisons showed that physical function (decreased SPPB and gait speed, increased chair rise time) worsened over time, particularly in participants with ≥2 nutritional deficits; however, no between-group differences were observed when individuals without deficit and those with either 1 or ≥2 deficits were compared. Our exploratory analysis on nutritional deficit-LGI interactions showed that, among people with ≥2 deficits, chair rise time was increased over time in participants with LGI (adjusted mean difference: 3.47; 95% CI: 1.03, 5.91; p = 0.017), compared with individuals with no LGI.

Conclusions: Accumulated deficits on vitamin D, homocysteine, and omega-3 PUFA were not associated with physical performance evolution in older adults, but they determined declined chair rise performance in subjects with low-grade inflammation.

Clinical Trial Registration: [https://clinicaltrials.gov/ct2/show/NCT00672685], identifier [NCT00672685].

Keywords: vitamin D, homocysteine, omega-3 fatty acids, physical performance, inflammation
INTRODUCTION

Decline in physical performance, as measured by lower extremity function, often marks the early stage of disability in older age (1, 2). It is crucial to identify modifiable factors, such as nutritional risk factors, and their underlying biological mechanisms leading to impaired mobility in older individuals. Indeed, several blood-based nutritional markers, such as homocysteine, vitamin D, and omega-3 polyunsaturated fatty acids (PUFAs), have gradually become the focus of research and clinical interventions (3, 4). Hyperhomocysteinemia (HHcy) has been associated with faster physical impairment, such as in walking test and chair rise test, in several longitudinal studies (5–7). Vitamin D deficiency has been cross-sectionally associated with poor physical performance (8–10); however, similar associations were not discovered in longitudinal studies (11, 12). Although the literature on omega-3 PUFAs is mixed, some studies have found increased omega-3 PUFAs was associated with low risk of mobility disability (13), poor Short Physical Performance Battery (SPPB) score, and slower gait speed over time (14).

Considering that the accumulation of deficits can be related with the ability of an individual to respond to stressors (15), it is possible that combined deficiencies in homocysteine, vitamin D, and omega-3 PUFAs would work synergistically to determine physical performance over time. This concept had been supported by the findings of a previous study, which have indicated that an increasing number of nutritional deficits were associated with faster cognitive decline (16). In another study, the nutritional index, which was constructed with 41 nutrition-related parameters from anthropometric, plasma, and nutrient intake measurements, had shown a stronger prediction of frailty and mortality risk compared with single nutritional parameters separately (15). Furthermore, there is a lack of studies investigating underlying mechanisms behind multi-nutritional deficits and physical impairment. Indeed, several physiological deteriorations that drive age-related mobility loss (17), including changes in the central nervous system (CNS) and chronic inflammation, have shown intimate associations with these nutritional markers (18, 19). For instance, HHcy can promote inflammation (20). Higher circulating levels of omega-3 were associated with larger hippocampal volume (21); on the other hand, smaller brain volumes were observed in people with low vitamin D status (22). Therefore, exploring the interactions between nutritional deficits and physiological alterations (i.e., chronic inflammation and CNS changes) might allow us to understand better their shared biological pathways leading to mobility decline.

The main objective of this study was to investigate the associations between multi-nutritional deficits (i.e., vitamin D deficiency, HHcy, and low omega-3 PUFA index) and physical performance in community-dwelling older adults over 5 years. In addition, we explored if the nutrition-physical performance associations varied according to the presence of low-grade inflammation (LGI) and brain imaging indicators.

METHODS

Design and Ethical Statement

This observational study used data from Multidomain Alzheimer Preventive Trial (MAPT), whose details have been described in previous publications (23, 24). Briefly, MAPT was a multicenter, 3-year randomized controlled trial that aimed to evaluate the protective effect of omega-3 PUFA supplementation and multidomain lifestyle interventions (exercise advice, cognitive training, and nutritional counseling), combined or alone, on cognitive decline in community-dwelling older adults (23). No significant effect of the interventions on cognitive function (24) or muscle strength (25) was found over 3 years. In this secondary analysis, 5-year follow-up data (3-year intervention plus an additional 2-year observation period after the end of interventions) were retrieved. The MAPT study was registered at ClinicalTrials.gov (no: NCT00672685), was approved by the French Ethical Committee located in Toulouse (CPP SOOM II), and was authorized by the French Health Authority. All the participants had signed informed consent.

Study Population

The MAPT study enrolled 1680 dementia-free adults aged ≥70 years, recruited from 13 memory centers in France and Monaco between 2008 to 2011, presenting at least one of the following conditions: spontaneous memory complaint, limitations in one instrumental Activities of daily living (such as disability in using telephone and transportation.), or slow gait speed (<0.8 m/s). In this study, 840 subjects who received the intervention of omega-3 supplementation and 454 subjects without nutritional markers measurement at baseline were not included; we finally considered data from 386 subjects into this study.

Measures

Definition of Nutritional Deficits

Three nutritional markers were used to define nutritional deficits: plasma 25-hydroxyvitamin D [25(OH)D], plasma homocysteine, and erythrocyte membrane omega-3 PUFA concentration. Details of nutritional marker assessment are described in Supplementary Materials. Nutritional deficits were determined at baseline according to the clinical cutoffs below: (1) vitamin D deficiency, if 25(OH)D <20 ng/ml (26); (2) HHcy, if homocysteine >14 µmol/L (27); (3) low omega-3 PUFA index, defined as omega-3 index (28) [% docosahexaenoic acid (DHA) + % eicosapentaenoic acid (EPA)] below the lower quartile of study population (≤4.87%) (16). The participants were then classified into three groups based on the counting of nutritional deficits: no deficit, 1 deficit, and ≥2 deficits.

Physical Performance

Three outcomes of physical performance were evaluated in this study: 4-m usual pace gait speed (in m/s), 5-repetition maximal chair rise time (in s), and Short Physical Performance Battery (SPPB) (29) score. The SPPB consisted of a walk test, a chair rise test, and a standing balance test with three challenging positions; each component was scored ranging from 0 (inability to complete
the test) to 4 (best performance). The overall SPPB score was calculated by summing the three component results (ranging from 0 to 12, higher score indicates better performance) (29). All the measurements were assessed at baseline, and after 6, 12, 24, 36, 48, and 60 months of follow-up.

Low-Grade Inflammation (LGI)
In this study, 293 of the 386 participants had C-reactive protein (CRP) measured at baseline, 6- and 12-month visits, using immuno-turbidimetry according to standard protocols. LGI (dichotomous variable) was defined as having at least two consecutively high CRP values (3–10 mg/L) between baseline and the 12-month visit, according to previous studies (30–32). Participants we could not categorize as LGI or non-LGI (e.g., people with CRP value >10 mg/L in the intermediate 6-month measurement) were excluded. Finally, we included 267 participants in the exploratory analysis.

Magnetic Resonance Imaging (MRI) Variables
Several MRI variables that had been reported to be associated with impaired mobility (18, 33, 34) were retrieved: total gray matter volume (cm³), hippocampal volume (mm³) and white matter hyperintensity (WMH) volume (cm³). Total intracranial volume (TICV) was also collected for model adjustment. The acquisition protocol for brain MRI has been detailed elsewhere (23) and in Supplementary Materials.

Confounders
Several confounding variables were selected: age, sex, MAPT intervention groups (i.e., multidomain intervention alone or placebo), level of education (ordinal), and body mass index (BMI; kg/m²). We also controlled the baseline physical activity status using a dichotomous variable (active or inactive) based on low physical activity component in the Fried’s frailty criteria (35). In the analysis for MRI variables, adjusted models included the confounders mentioned above as well as TICV.

---

**TABLE 1 | Baseline characteristics of the study population**

| Total population (N = 386) | Number of nutritional deficits^2 | p-value^3 |
|---------------------------|---------------------------------|-----------|
|                           | No deficit (N = 84) | 1 deficit (N = 153) | ≥2 deficits (N = 149) | |
| **Age (years)** | 75.6 (4.5) | 74.8 (4.1)^a | 75.0 (4.3)^b | 76.7 (4.8)^c,d | 0.001 |
| **Sex (female)** | 263 (68.1%) | 66 (78.6%) | 111 (72.6%) | 86 (57.7%) | 0.002 |
| **MAPT groups** | 191 (49.5%) | 40 (47.6%) | 77 (50.3%) | 74 (49.7%) | 0.922 |
| Multidomain intervention | | | | |
| Placebo | 195 (50.5%) | 44 (52.4%) | 76 (49.7%) | 75 (50.3%) | |
| **Education (n = 376)** | 80 (21.3%) | 30 (19.9%) | 3 (25.9%) | 0.407 |
| No diploma or primary school certificate | | | |
| Secondary education | 122 (32.4%) | 28 (34.1%) | 47 (31.1%) | 47 (32.9%) | |
| High school diploma | 58 (15.4%) | 12 (14.6%) | 29 (19.2%) | 17 (11.9%) | |
| University level | 116 (30.9%) | 29 (35.4%) | 45 (29.8%) | 42 (29.3%) | |
| Body mass index (kg/m²) | 26.1 (3.9) | 25.1 (4.0)^a | 25.9 (3.9) | 26.8 (3.8)^b | 0.003 |
| No deficit (N = 84) | 26.1 (3.9) | 25.1 (4.0)^a | 25.9 (3.9) | 26.8 (3.8)^b | |
| **CDR status: 0.5 (mild cognitive impairment)** | 155 (40.2%) | 27 (32.1%) | 32 (22.8%) | 34 (33.7%) | 0.234 |
| **Physical status: inactive (n = 384)** | 53 (13.8%) | 6 (6.0%) | 22 (14.5%) | 26 (17.5%) | 0.051 |
| **Nutritional risk factors** | 23.2 (12.5) | 30.8 (12.2)^a,b | 25.2 (12.7)^c | 16.9 (8.8)^b,c | <0.001 |
| Vitamin D (ng/ml) | 163 (42.2%) | 0 (0%) | 57.3 (73.7%) | 106 (71.1%) | <0.001 |
| Homocysteine (µmol/L) | 15.64 (5.27) | 11.32 (1.41)^a,b | 15.31 (4.88)^a,c | 18.41 (5.32)^c | <0.001 |
| Hyperhomocysteinemia (>14 µmol/L) | 220 (57.0%) | 0 (0%) | 85 (55.6%) | 135 (90.6%) | <0.001 |
| Omega-3 index (%) | 5.86 (1.44) | 6.61 (1.13)^a | 6.21 (1.25)^b | 5.08 (1.14)^a-b | <0.001 |
| <4.87 (lower quartile) | 98 (25.4%) | 0 (0%) | 11 (7.2%) | 87 (58.4%) | <0.001 |
| **Physical performance** | 10.7 (1.7) | 10.9 (1.5) | 10.7 (1.7) | 10.5 (1.8) | 0.156 |
| SPPB score, 0–12 (n = 378) | 1.08 (0.25) | 1.10 (0.25) | 1.08 (0.25) | 1.06 (0.25) | 0.590 |
| Gait speed (m/s) (n = 383) | 11.6 (3.9) | 10.4 (2.4)^a | 11.6 (3.9) | 12.3 (4.5)^a | 0.004 |

---

1 Values presented in number (%) for categorical variables or mean (standard deviation) for continuous variables; CDR, clinical dementia rating scale; MAPT, Multidomain Alzheimer Preventive Trial; SPPB, Short Physical Performance Battery.

2 Cutoff of nutritional deficits: Vitamin D <20 ng/ml, homocysteine >14 µmol/L, omega-3 index ≥ lower quartile (4.87%).

3 P-value based on ANOVA or Chi-square test across groups; a,b,c same letters indicate significant differences between groups (p < 0.05).
**TABLE 2** | Linear mixed-effect regressions examining cross-sectional associations between nutritional deficits\(^4\) and physical performance at baseline.

| Outcome: SPPB score (0–12) | Unadjusted model | Adjusted model\(^5\) |
|---------------------------|------------------|---------------------|
| Nutritional deficits      | \(\beta\) 95% CI | \(p\)-value           |
| No deficit                | Ref. – – –      | Ref. – – –            |
| 1 deficit                 | –0.20 –0.60, 0.19 | 0.318               |
| \(\geq 2\) deficits      | –0.59 –0.99, –0.20 | 0.004               |
| Outcome: gait speed (m/s) |                  |                     |
| Nutritional deficits      | \(\beta\) 95% CI | \(p\)-value           |
| No deficit                | Ref. – – –      | Ref. – – –            |
| 1 deficit                 | –0.01 –0.07, 0.05 | 0.703               |
| \(\geq 2\) deficits      | –0.06 –0.12, –0.01 | 0.041               |
| Outcome: chair rise time (s) |      |                     |
| Nutritional deficits      | \(\beta\) 95% CI | \(p\)-value           |
| No deficit                | Ref. – – –      | Ref. – – –            |
| 1 deficit                 | 0.70 –0.22, 1.61 | 0.137               |
| \(\geq 2\) deficits      | 1.58 0.66, 2.50  | 0.001               |

\(\text{CI, confidence interval; Ref, reference group; SPPB, Short Physical Performance Battery.}\)

\(^{4}\text{Cutoff of nutritional deficits: vitamin D < 20 ng/ml, homocysteine > 14 \mu\text{mol/L}, omega-3 index \leq lower quartile (4.87%).}\)

\(^{5}\text{Adjustments for age, sex, Multidomain Alzheimer Preventive Trial (MAPT) groups, education, body mass index, and physical activity status.}\)

---

**Statistical Analysis**

Baseline characteristic comparisons across the nutritional deficit groups were performed by Chi-square test for categorical variables and ANOVA for continuous variables. Linear mixed-effect regressions, including a random effect at participant level and a random slope on time, were conducted to evaluate the cross-sectional and longitudinal associations between nutritional deficits and physical performance outcomes.

A series of exploratory analyses were conducted to explore the roles of LGI (among 267 subjects with available CRP data) and imaging markers (among 164 subjects with MRI measures) in the association between nutritional deficits and physical performance. We first performed logistic regressions to examine the association between nutritional deficits and LGI. Then, an interaction term by LGI and nutritional deficits was introduced into the same mixed-effect models for main analysis; only assessments of the outcomes performed at 12 months and after were considered for this analysis. For imaging markers, cross-sectional associations with nutritional deficits were tested by linear mixed-effect regressions (with random intercept for the center effect). Longitudinal analysis considering the interaction effect (MRI variable \(\times\) nutritional deficits) on physical performance was examined by linear mixed-effect regressions (three-level nested model, with the participants nested into the center); for participants who received MRI scans at 6-month visit and 12-month visit, measurements of physical performances before MRI scans were excluded from the analysis. Statistical significance was defined as \(p < 0.05\); the \(p\)-values of between-group mean differences are presented after false discovery rate correction (36). All the statistical analyses were performed with Statistical Analysis Software (SAS) version 9.4 (Cary, NC, USA).

**RESULTS**

Among the overall 386 participants, 21.8% \((n = 84)\) had no nutritional deficit at baseline, 39.6% \((n = 153)\) presented 1 deficit, and 38.6% \((n = 149)\) presented \(\geq 2\) deficits. Participants with more nutritional deficits tended to be older and male, and to present with higher BMI (Table 1). At baseline, compared with those without any deficit, having \(\geq 2\) deficits was associated with longer chair rise time, i.e., poor chair rise performance (Table 2). No cross-sectional associations were found with SPPB score or gait speed.

After 5 years of follow-up, decreased SPPB score and gait speed, and increased chair rise time were observed among the participants with \(\geq 2\) nutritional deficits (Table 3). \(P\)-values for linear trend for within-group change in physical performance outcomes were all significant \((p \text{ for trend } < 0.001)\). However, no significant between-group differences were discovered for the changes in SPPB, gait speed, and chair rise time when individuals without deficit and those with either 1 or \(\geq 2\) deficits were compared (Table 3).

In the logistic regression for LGI and nutritional deficits, people with \(\geq 2\) deficits had higher likelihood of having LGI (adjusted OR = 2.53; 95% CI: 1.01 to 6.33; \(p = 0.006\); **Supplementary Table 1**), compared with those without deficits. Significant interaction effects by LGI and nutritional deficits on chair rise time were observed in the linear mixed-effect regression. Among people with \(\geq 2\) deficits, the adjusted mean difference in chair rise time over 5 years...
**DISCUSSION**

To our knowledge, this is the first study to investigate the associations between accumulated nutritional deficits and physical performance in community-dwelling older adults. We discovered that presenting two or more nutritional deficits (i.e., vitamin D deficiency, HHcy, and low omega-3 PUFAs index) was cross-sectionally associated with poor chair rise performance at baseline. We did not observe associations of combined nutritional deficits with mobility decline over 5 years; however, our exploratory analysis found that the association of nutritional deficits with chair rise performance could vary according to LGI status, with a more pronounced increase in chair rise time (worse performance; 0.69 s more per year) among older adults with ≥2 deficits and LGI compared with their non-LGI counterparts.

The relationship between the nutritional markers investigated in our study and physical performance has mixed findings in the literature (8–13). In this study, although the between-group differences did not reach significance, within-group changes for all the three physical performance outcomes showed higher overtime declines as the number of deficits increased (p for trend <0.001). Noteworthy, after the 5-year follow-up, more than half of the participants with ≥2 nutritional deficits became octogenarians whose mobility tends to decline faster than in younger people (17). On the other hand, our exploratory analysis found that LGI, an important mechanism implicated in both aging (37) and mobility disability (17, 38), contributed to this accelerated decline of physical performance in older individuals with combined nutritional deficits. This finding suggests that both the presence of nutritional deficits and chronic inflammation contribute to physical impairment. Indeed, omega-3 PUFAs and HHcy had been proposed to affect mobility outcomes through inflammatory pathway. Omega-3 PUFAs can suppress chronic inflammation, further inhibiting muscle catabolism (39); HHcy can lead to inflammation by causing reactive oxygen species accumulation and pro-inflammatory cytokine secretion (4, 20). Although vitamin D is well-known for its metabolic roles in muscle synthesis and bone formation (3), the recent evidence had suggested it has immunomodulatory effects by regulating both innate and adaptive immunity (40). On the other hand, it is plausible that LGI status is independent of the presence of nutritional deficits, but that their joint effect enhances the detrimental impact on physical function. For example, accelerated muscle catabolism caused by inflammation (41), combined with muscle weakness caused by vitamin D...
deficiency (10), can lead to faster decline in overall muscle function and physical performance.

Our cross-sectional and exploratory analyses only observed significant associations between nutritional deficits and chair rise performance, suggesting nutritional deficits would affect physical performance through a muscle quality-related mechanism rather than changes in the central nervous system. This is also supported by our findings related to MRI indicators, which showed no significant interaction between brain volumes and nutritional deficits on changes in physical performance over time. Compared with gait speed, a functional vital sign (42) relying on complex movement controls with executive function involved (43), chair rise test is a more specific measure of muscle function (44), strongly determined by muscle mass and power in older adults (45, 46). Another possible explanation for the limited findings on change in SPPB is that only a few participants of this study had mobility limitation at baseline, with 6% having SPPB ≤7 (1) and about 20% having SPPB ≤9 (47). Although it is possible that people who started having mobility limitations would decline faster in mobility (48), the associations of nutritional deficits with mobility limitation in mobility-impaired individuals require further investigations.

A number of strengths should be mentioned in our study. We evaluated multiple nutritional deficits, assessed by three blood-based biomarkers, and several measures of physical performance in older adults over 5 years. In addition, we explored the potential role of inflammatory and neuroimaging markers in nutrition-physical performance associations. However, some limitations are worth mentioning. First, this is an observational study with data retrieved from a randomized controlled trial. Even though MAPT multidomain intervention did not affect physical performance (25), our results need to be interpreted cautiously, since the exercise advice and nutritional counseling part of the multidomain intervention could have modified the nutritional markers overtime. In order to minimize this bias, MAPT group allocation was added as a confounder in the models. Residual confounding may not be excluded, since some other potential confounders, such as nutritional supplementation (except for omega-3 PUFAs), inadequate dietary protein intake, and smoking and drinking habits (12, 49), were not available. Finally, the MAPT study enrolled a sample of community-dwelling older adults at risk of cognitive decline, which might affect the generalizability of our findings to other populations.

To conclude, this study did not observe prospective associations between combined nutritional deficits (vitamin D deficiency, HHcy, and low omega-3 index) and overtime mobility decline in community-dwelling older adults. However, different trajectories of chair rise performance were observed among people with two or more deficits, once the presence of chronic, low-grade inflammation was considered. Future studies that will investigate nutritional deficits and physical impairment focused on older adults with different conditions characterized by LGI, including subjects with mobility limitation, could shed light on this topic.

DATA AVAILABILITY STATEMENT

Data described in the article, code book, and analytic code will be made available upon request pending application and approval. Requests to access these datasets should be directed to Wan-Hsuan Lu, wan-hsuan.lu1@univ-tlse3.fr.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by French Ethical Committee located in Toulouse (CPP SOOM II). The patients/participants provided their written informed consent to participate in this study.

MAPT/DSA GROUP

MAPT study group: principal investigator: Bruno Vellas (Toulouse); coordination: Sophie Guyonnet; project leader: Isabelle Carrié; CRA: Lauréane Brigitte; investigators: Catherine Faisant, Françoise Lala, Julien Delrieu, and Hélène Villars; psychologists: Emeline Combrouze, Carole Badule, and Audrey Zueras; methodology, statistical analysis, and data management: Sandrine Andrieu, Christelle Cantet, and Christophe Morin; multidomain group: Gabor Abellan Van Kan, Charlotte Dupuy, and Yves Rolland (physical and nutritional components), Céline Caillaud, Pierre-Jean Ousset (cognitive component), and Françoise Lala (preventive consultation) (Toulouse). The cognitive component was designed in collaboration with Sherry Willis from the University of Seattle, and Sylvie Belleville, Brigitte Gilbert, and Francine Fontaine from the University of Montréal. Co-investigators in associated centers: Jean-François Dartigues, Isabelle Mercet, Fleur Delva, Alexandre Foubert, and Sandrine Cerda (Bordeaux); Marie-Noëlle-Cuffi, Corinne Costes (Castres); Olivier Rouaud, Patrick Manckoundia, Valérie Quipourt, Sophie Marillier, and Evelyne Franon (Dijon); Lawrence Bories, Marie-Laure Pader, Marie-France Basset, Bruno Lapoujade, Valérie Faure, Michael Li Yung Tong, Christine Malicik-Loiseau, and Evelyne Cazaban-Campistron (Foix); Françoise Desclaux and Colette Blatge (Lavau); Thierry Dantoine, Cécile Laubarie-Mouret, Isabelle Saulnier, Jean-Pierre Clément, Marie-Agnès Picat, Laurence Bernard-Bourzeix, Stéphanie Willebois, Iléana Désormais, and Noëlle Cardinaud (Limoges); Marc Bonnefoy, Pierre Livet, Pascale Rebaudet, Claire Gédéon, Catherine Burdet, and Flavien Terracol (Lyon), Alain Pesce, Stéphanie Roth, Sylvie Chaillou, and Sandrine Louchart (Monaco); Kristel Sudres, Nicolas Lebrun, and Nadège Barro-Belayguely (Montauban); Jacques Touchon, Karim Bennys, Audrey Gabelle, Aurélie Romano, Lynda Touati, Cécilia Marelli, and Cécile Pays (Montpellier); Philippe Robert, Franck Le Duff, Claire Gervais, and Sébastien Gonfrier (Nice); Yannick Gasnier, Serge Bordes, Danièle Begorre, Christian Carpuat, Khaled Khales, Jean-François Lefèvre, Samira Misbah El Idrissi, Pierre Skolil, and Jean-Pierre Salles (Tarbes). MRI group: Carole Dufouil (Bordeaux); Stéphanie Lehéricy, Marie Chupin, Jean-François Mangin, and Ali Bouhaya (Paris); Michèle Allard (Bordeaux);
FUNDING

This study was performed in the context of the Inspire Program, a research platform supported by grants from the Region Occitanie/Pyrénées-Méditerranée (Reference number: 1901175) and the European Regional Development Fund (ERDF) (Project number: MP0022856). The MAPT study was supported by grants from the Gérontopôle of Toulouse, the French Ministry of Health (PHRC 2008, 2009), Pierre Fabre Research Institute (manufacturer of the omega-3 supplement), ExonHit Therapeutics SA, and Avid Radiopharmaceuticals Inc. The promotion of this study was supported by the University Hospital Center of Toulouse. The data sharing activity was supported by the Association Monegasque pour la Recherche sur la maladie Alzheimer’s (AMPA) and the INSERM-University of Toulouse III UMR 1295 Unit.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2021.771470/full#supplementary-material
20. Veeranki S, Tyagi SC. Defective homocysteine metabolism: potential implications for skeletal muscle function. Int J Mol Sci. (2013) 14:15074–91. doi: 10.3390/ijms14071504
21. Macaron T, Giudici KV, Bowman GL, Sinclair A, Stephan E, Vellas B, et al. Associations of Omega-3 fatty acids with brain morphology and volume in cognitively healthy older adults: a narrative review. Ageing Res Rev. (2021) 67:101300. doi: 10.1016/j.arr.2021.101300
22. Croll PH, Boelens M, Vernooij MW, van de Rest O, Zillikens MC, Ikram MA, et al. Associations of vitamin D deficiency with MRI markers of brain health in a community sample. Clin Nutr. (2021) 40:72–8. doi: 10.1016/j.clnu.2020.04.027
23. Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. Mapt study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prev Alzheimer’s Dis. (2014) 1:13–22. doi: 10.14283/jpad.2014.3.4
24. Andrieu S, Guyonnet S, Doyle N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. (2017) 16:377–89. doi: 10.1016/S1474-4422(17)30040-6
25. Rolland Y, Barreto P de S, Maltais M, Guyonnet S, Cantet C, Andrieu S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain lifestyle intervention on muscle strength in older adults: secondary analysis of the multidomain Alzheimer preventive trial (MAPT). Nutrients. (2019) 11:1933. doi: 10.3390/nu11091931
26. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. (2011) 96:1911–30. doi: 10.1210/jc.2011-0385
27. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. (2002) 346:476–83. doi: 10.1056/NEJMoa011613
28. Harris WS, Von Schacky C. The omega-3 index: a new risk factor for cardiovascular disease detection and prevention. Exp Gerontol. (2020) 149:111090. doi: 10.1016/j.exger.2020.111090
29. Bektas A, Schurman SH, Sen R, Ferrucci L. Aging, inflammation and the environment. Exp Gerontol. (2018) 105:10–8. doi: 10.1016/j.exger.2017.12.015
30. Osawa Y, Sembra RD, Fantoni G, Candia J, Biancotto A, Tanaka T, et al. Plasma proteomic signature of the risk of developing mobility disability: a 9-year follow-up. Aging Cell. (2020) 19:e13132. doi: 10.1111/acc.13132
31. Dupont J, Dedeyne L, Dalle S, Koppo K, Gielen E. The role of omega-3 in the prevention and treatment of sarcopenia. Aging Clin Exp Res. (2019) 31:825–36. doi: 10.1007/s40520-019-01146-1
32. Giudici KV, de Souto Barreto P, Guerville F, Beard J, Araujo de Carvalho I, Andrieu S, et al. Mapt study: a multidomain approach for preventing Alzheimer’s disease: associations of C-reactive protein and amyloid plaques in the brain and chair rise performance in nondementia older adults with spontaneous memory complaints. J Gerontol A Biol Sci Med Sci. (2017) 72:278–83. doi: 10.1093/gerona/gbw195
33. Whitney SL, Wrisley DM, Marchetti GF, Gee MA, Redfern MS, Furman JM. Clinical measurement of sit-to-stand performance in people with balance disorders: validity of data for the Five-Times-Sit-to-Stand Test. Phys Ther. (2005) 85:1034–45. doi: 10.1093/ptj/85.10.1034
34. Sekhon H, Launay CP, Chabot J, Allali G, Beauchet O. Motoric cognitive risk syndrome: could it be defined through increased five-times-sit-to-stand test, rather than slow walking speed? Front Aging Neurosci. (2019) 11:434. doi: 10.3389/fnagi.2018.00434
35. von Berens Á, Cederholm T, Fielding RA, Gustafsson T, Kirn D, Laussen J, et al. Physical performance and serum 25(OH)D vitamin D status in community dwelling older mobility limited adults: a cross-sectional study. J Nutr Heal Aging. (2018) 22:1–7. doi: 10.1016/j.jnha.2016-0849-0
36. Tiainen K, Raitanen J, Vaara E, Hervonen A, Jylhä M. Longitudinal changes in mobility among nonagenarians: the Vitality 90+ Study. BMC Geriatr. (2015) 15:1–8. doi: 10.1186/s12877-015-0116-y
37. Damm TTL, Von Mühlen D, Barrett-Connor EL. Sex-specific association of serum vitamin D levels with physical function in older adults. Osteoporos Int. (2009) 20:751–60. doi: 10.1007/s00198-007-0749-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Lu, Giudici, Rolland, Guyonnet, Mangin, Vellas and de Souto Barreto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.